Breaking News Instant updates and real-time market news.

OSTK

Overstock.com

$17.77

0.54 (3.13%)

, UXIN

Uxin

$2.36

-0.24 (-9.23%)

08:45
07/17/19
07/17
08:45
07/17/19
08:45

Largest borrow rate increases among liquid names

Latest data shows the largest indicative borrow rate increases among liquid option names include: Overstock com (OSTK) 88.36% +0.20, FAS (FAS) 1.51% +0.11, Uxin Ltd (UXIN) 16.50% +0.08, ProShares UltraShort DJ UBS Crude Oil (SCO) 4.10% +0.07, Maxar Technologies (MAXR) 5.24% +0.03, United States Oil Fund (USO) 2.14% +0.03, NIO (NIO) 33.32% +0.02, ArQule (ARQL) 1.12% +0.02, SPDR S&P Metals and Mining (XME) 0.68% +0.02, and Lannett (LCI) 1.78% +0.02.

OSTK

Overstock.com

$17.77

0.54 (3.13%)

UXIN

Uxin

$2.36

-0.24 (-9.23%)

SCO

Scor ADR

$16.74

0.6 (3.72%)

MAXR

Maxar Technologies

$8.82

-0.385 (-4.18%)

USO

United States Oil Fund

$12.07

-0.245 (-1.99%)

NIO

NIO Inc.

$3.29

-0.1 (-2.95%)

ARQL

ArQule

$10.63

0.03 (0.28%)

XME

SPDR S&P Metals & Mining

$28.09

0.31 (1.12%)

LCI

Lannett

$5.75

-0.06 (-1.03%)

  • 06

    Aug

OSTK Overstock.com
$17.77

0.54 (3.13%)

07/10/19
DADA
07/10/19
NO CHANGE
Target $48
DADA
Buy
Overstock tech stack would be valuable to strategic buyers, says DA Davidson
DA Davidson analyst Tom Forte reiterated his Buy rating and $48 price target on shares of Overstock.com (OSTK) following the company's announcement regarding its awards for its technology, stating that he sees the awards as consistent with a prior Chain Store Age study that found its website had among the fastest response times on Black Friday. Forte said that he believes Overstock's technology would "enable the three potential suitors we have written the most about," namely Costco (COST), Target (TGT), and TJMaxx (TJX), to advance their own e-commerce efforts, among other things.
07/16/19
MAXM
07/16/19
INITIATION
Target $34
MAXM
Buy
Overstock.com resumed with a Buy at Maxim
Maxim analyst Allen Klee resumed coverage of Overstock.com with a Buy rating, saying he expects the company's Retail e-commerce segment to shift to EBITDA profitability and for its blockchain tZero assets to gain "multiple product approvals" this year. The analyst notes that his price target of $34 is reduced from $75 under prior coverage and reflects expectations of a slower pick-up for tZERO as well as greater Medici projected losses, but believes that the blockchain investment has the potential to be a significant earnings contributor in the longer term.
03/20/19
DADA
03/20/19
NO CHANGE
Target $51
DADA
Buy
Overstock.com 10K filing anticipates Q1 revenue decline, says DA Davidson
DA Davidson analyst Tom Forte kept his Buy rating and $51 price target on Overstock.com after its 10-K filing release, which anticipates Q1 revenue to decline by 17%-19% from last year's levels and implies $361M-$370M vs. $421M consensus. The analyst cites the management's "intention to continue to scale back sales and marketing expenses and increase operating efficiencies" with staff reductions, but also remains positive on its Medici Ventures vision to develop blockchain technology, as highlighted in the company's Q4 earnings call.
03/19/19
DADA
03/19/19
NO CHANGE
Target $51
DADA
Buy
Overstock.com price target lowered to $51 from $58 at DA Davidson
DA Davidson analyst Tom Forte lowered his price target on Overstock.com to $51 after its Q4 earnings miss, modeling all of the reduction to its legacy e-commerce business while maintaining the valuation on its Medici Ventures business at $25 per share. The analyst also keeps his Buy rating on the company, noting the progress and plans for tZERO provide "ample reason" that the share price "does not properly reflect the value of its portfolio". Forte maintains his positive stance related to Medici's completed first cryptobond offering, completed first crypto stocking, and being "one of the first to complete a securitized token offering and to launch an alternative trading system."
UXIN Uxin
$2.36

-0.24 (-9.23%)

04/16/19
04/16/19
NO CHANGE

Uxin exaggerates auto volumes by as much as 40%, says J Capital
J Capital Research analyst Anne Stevenson-Yang believes Uxin exaggerates the volume of auto sales its processes by as much as 40%. After speaking to dealers, former executives, and salespeople from competing companies, the analyst believes Uxin is "basically a Craigslist of autos," listing cars that are being offered on multiple websites, for free. Further, financial statements for Uxin's operating companies in China "show a staggering level of debt that puts the company at risk of collapse," Stevenson-Yang tells investors in a research note. She admits to not knowing how to ascribe a valuation to the stock since the company "is so dishonest." Investors should "race to the exits," says Stevenson-Yang. Uxin in early trading is up 1c to $3.06.
04/24/19
04/24/19
NO CHANGE

Uxin mentioned cautiously again by J Capital
J Capital Research has published a follow-up report on its short call on Uxin to respond to the company's response to the firm's April 16 short report. In the follow-up, J Capital's Anne Stevenson-Yang writes in part: "Uxin's response on the number of cities covered - it says 900 - contradicts what Investor Relations told us just one week before the report." Reference Link
03/12/19
FBCO
03/12/19
INITIATION
Target $7.7
FBCO
Outperform
Uxin initiated with an Outperform at Credit Suisse
Credit Suisse initiated Uxin with an Outperform and $7.70 price target.
03/14/19
JPMS
03/14/19
NO CHANGE
Target $8
JPMS
Overweight
JPMorgan sees over 70% upside in Uxin, ups price target to $8
JPMorgan analyst Nick Lai raised his price target for Uxin to $8 from $7 following the company's better than expected Q4 results. The stock closed yesterday down 2c to $4.60. The analyst increased his revenue forecasts for 2019 and 2020 and believes Uxin will turn to profit in Q4 of 2019. For 2019, Lai forecasts intercity transaction will quadruple while believing same city should also surge by greater than 30%. He keeps an Overweight rating on Uxin shares.
SCO Scor ADR
$16.74

0.6 (3.72%)

MAXR Maxar Technologies
$8.82

-0.385 (-4.18%)

03/01/19
03/01/19
DOWNGRADE

Fly Intel: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. L Brands (LB) downgraded to Market Perform from Outperform at Bernstein with analyst Jamie Merriman saying her Outperform rating was based on a view that investors were paying for Bath & Body Works with a free option on Victoria's Secret. 2. American Airlines (AAL) and Delta Air Lines (DAL) downgraded to Hold from Buy at Deutsche Bank. 3. Devon Energy (DVN) downgraded to Sector Perform from Outperform at RBC Capital. 4. O'Reilly Automotive (ORLY) downgraded to Neutral from Overweight at Atlantic Equities with analyst Sam Hudson citing valuation and raised his price target to $400 from $370. 5. Maxar Technologies (MAXR) downgraded to Hold from Speculative Buy at TD Securities and to Underperformer from Neutral at CIBC. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
03/01/19
03/01/19
DOWNGRADE
Target $9

Hold
Maxar Technologies downgraded to Hold at TD Securities after disappointing Q4
As previously reported, TD Securities analyst Tim James downgraded Maxar Technologies to Hold from Speculative Buy and lowered his price target to $9 from $18.50 after its below-consensus Q4 results. The analyst says his previous constructive thesis attributing the company's weakness to the divestable GEO comsat business was incorrect as the company indicated it will continue to operate it at a loss. James added that the EBITDA of Maxar's Services and Imagery segment was also soft and recommends that investors await for evidence of improvement before considering buying shares again.
03/01/19
TDSI
03/01/19
DOWNGRADE
TDSI
Hold
Maxar Technologies downgraded to Hold from Speculative Buy at TD Securities
03/01/19
CIBC
03/01/19
DOWNGRADE
CIBC
Underperformer
Maxar Technologies downgraded to Underperformer from Neutral at CIBC
USO United States Oil Fund
$12.07

-0.245 (-1.99%)

NIO NIO Inc.
$3.29

-0.1 (-2.95%)

04/04/19
04/04/19
UPGRADE

Fly Intel: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Facebook (FB) upgraded to Buy from Neutral at Guggenheim with analyst Michael Morris saying investors will continue to gain comfort with the incremental financial risk created by Facebook's content and privacy concerns. 2. NIO Inc. (NIO) upgraded to Buy from Neutral at Citi and to Neutral from Underperform at BofA/Merrill. 3. Ingersoll-Rand (IR) upgraded to Buy from Neutral at BofA/Merrill with analyst Andrew Obin citing premium core and earnings growth. 4. EOG Resources (EOG) upgraded to Buy from Hold at Tudor Pickering. 5. Signature Bank (SBNY) upgraded to Overweight from Neutral at JPMorgan with analyst Steven Alexopoulos raising his price target for the shares to $150 from $133. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
05/29/19
05/29/19
DOWNGRADE

Fly Intel: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. General Mills (GIS) downgraded to Sell from Neutral at Goldman Sachs with analyst Jason English saying that after a period of outperformance from sequential improvement in the company's core business and the impact of its acquisition of Blue Buffalo, General Mills is entering its next "chapter" of "mounting deceleration." 2. NIO Inc. (NIO) downgraded to Underperform from Neutral at BofA/Merrill with analyst Ming Hsun Lee saying he expects weak orders for the ES8 and ES6 due to EV purchase subsidy cuts, less cash flow from reduced car sales, increased competition from Tesla's (TSLA) Model 3 in 2020, and views valuation as "rich." 3. American Campus (ACC) downgraded to Market Perform from Outperform at JMP Securities with analyst Aaron Hecht saying his firm's checks at UC Berkeley indicate that the 6,000 bed RFP will likely end up being fee-based development, which takes one of his previously expected catalysts off the table. 4. Atlassian (TEAM) downgraded to Neutral from Buy at BTIG with analyst Edward Parker saying after a "great run" of over 100% in the last 12 months, the risk-reward on the stock has turned more "balanced." 5. Ericsson (ERIC) downgraded to Sell from Neutral at New Street. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
05/28/19
BOFA
05/28/19
DOWNGRADE
BOFA
Underperform
NIO Inc. downgraded to Underperform from Neutral at BofA/Merrill
05/29/19
05/29/19
DOWNGRADE
Target $3

Underperform
NIO Inc. downgraded to Underperform on shipment downside at BofA/Merrill
As previously reported, BofA/Merrill downgraded NIO Inc. (NIO) to Underperform from Neutral and cut its price target to $3 from $6.20. Analyst Ming Hsun Lee expects weak orders for the ES8 and ES6 due to EV purchase subsidy cuts, less cash flow from reduced car sales, increased competition from Tesla's (TSLA) Model 3 in 2020, and views valuation as "rich." Lee lowered his volume sales forecast for 2019 by 20% to 27k units and 2020 by 45% to 40k units.
ARQL ArQule
$10.63

0.03 (0.28%)

06/14/19
ROTH
06/14/19
NO CHANGE
Target $13
ROTH
Buy
ArQule price target raised to $13 from $10 at Roth Capital
Roth Capital analyst Tony Butler said he is optimistic about the efficacy and safety profile of ARQ 531 following the company's presentation of trial data, investor call and his talk with management. However, he thinks the key uncertainty now is durability of responses, which he highlights as important given the refractory population and the fact that ibrutinib was also based on survival data. He has raised his view of the probability of success for ARQ 531 to 50% from 33% previously and increased his price target to $13 on ArQule shares, on which he keeps Buy rating.
06/17/19
ROTH
06/17/19
NO CHANGE
Target $20
ROTH
Buy
ArQule price target raised to $20 from $10 at Roth Capital
Roth Capital analyst Tony Butler raised his price target for ArQule to $20 from $10 after the company presented updated data from its first-in-human, single-arm Phase 1 study of ARQ 531, the first oral reversible BTK inhibitor for both wild-type and ibrutinib-resistant BTK-c481S mutation. The analyst reiterates a Buy rating on the shares.
06/19/19
RBCM
06/19/19
NO CHANGE
Target $12
RBCM
Outperform
ArQule price target raised to $12 from $10 at RBC Capital
RBC Capital analyst Gregory Ranza raised his price target on ArQule to $12 and kept his Outperform rating, citing the company's "impressive data" and "high enthusiasm" for its BTKi program ARQ 531 in B-cell malignancies demonstrated at the European Hematology Association Congress this week. The analyst adds that his new price target reflects the improving prospects for ARQ 531 success, along with his "increasing confidence" that an effective path awaits ArQule toward a "meaningful" Chronic Lymphocytic Leukemia market opportunity.
05/29/19
RILY
05/29/19
NO CHANGE
Target $11
RILY
Buy
ArQule price target raised to $11 from $6.75 at B. Riley FBR
B. Riley FBR analyst George Zavoico raised his price target for ArQule to $11 from $6.75 ahead of what he expects will be "positive" Phase I safety and efficacy results for ARQ531 at the European Hematology Association conference in June. The analyst reiterates a Buy rating on the shares.
XME SPDR S&P Metals & Mining
$28.09

0.31 (1.12%)

LCI Lannett
$5.75

-0.06 (-1.03%)

08/20/18
BMOC
08/20/18
NO CHANGE
BMOC
Market Perform
Lannett price target lowered to $8 from $19 at BMO Capital
BMO Capital analyst Gary Nachman said JSP's decision to not renew its agreement with Lannett (LCI) and go with Amneal Pharmaceuticals (AMRX) is an "unfortunate development" that impacts three products, including Levothyroxine, which accounts for about 35-40% of Lannett revenue and is "very profitable." He lowered his estimates "significantly" due to this "major setback" and cut his price target on Lannett shares to $8 from $19 while maintaining a Market Perform rating on the shares.
08/20/18
08/20/18
DOWNGRADE

Market Perform
Lannett downgraded to Market Perform as JSP walks away from renewal at Raymond James
As previously reported, Raymond James analyst Elliot Wilbur downgraded Lannett to Market Perform from Outperform after Jerome Stevens terminated its strategic distribution agreement with the company, a deal that provided Lannett with several key products but mainly levothyroxine, which is expected to account for 35% of FY18 sales and 44% of gross profit. From a monetary perspective, the analyst believes it makes "zero sense" why JSP would walk away from the deal, inflicting significant damage on its own holdings of Lannett shares. This suggests either JSP has no confidence in the recovery value of its holdings from current levels or has sold down or hedged a substantial portion of its holdings despite prior representations from Lannett management to the contrary, Wilbur contends.
05/13/19
WELS
05/13/19
NO CHANGE
WELS
Lawsuit against Teva, others to hit generic drug stocks, says Wells Fargo
Wells Fargo analyst David Maris believes the lawsuit by 44 states against 20 generic drugmakers will weigh on generic drug stocks this week and remain an "overhang issue for some time." Actual penalties and damages are impossible to calculate, but could be material, Maris tells investors in a research note. The analyst spoke to the Connecticut attorney general's office this morning and learned they are preparing for trial in these cases. Language the attorney general has used, such as "unprecedented" and his desire to clawback all gains from collusion, should be indicative of the states' intent, Maris writes. He believes that for a sector that is generally highly levered, and with some companies named already facing an overhang from opioid litigation like Teva (TEVA), this is "especially unwelcome news."
03/19/19
RHCO
03/19/19
INITIATION
Target $9
RHCO
Hold
Lannett initiated with a Hold at SunTrust
SunTrust analyst Gregg Gilbert started Lannett with a Hold rating and $9 price target. The analyst says that while the stock's most important overhang has been removed with the loss of levothyroxine, he sees the risk/reward as relatively balanced at current share levels.

TODAY'S FREE FLY STORIES

11:37
11/18/19
11/18
11:37
11/18/19
11:37
General news
3-Month Bill Auction Total Amount data reported »

3-Month Bill Auction…

11:37
11/18/19
11/18
11:37
11/18/19
11:37
General news
6-Month Bill Auction Total Amount data reported »

6-Month Bill Auction…

WMT

Walmart

$120.41

1.52 (1.28%)

11:36
11/18/19
11/18
11:36
11/18/19
11:36
Periodicals
Three dead following shooting at Walmart in Duncan, OK, Fox 25 reports »

Officials with the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CLDR

Cloudera

$8.80

0.04 (0.46%)

11:35
11/18/19
11/18
11:35
11/18/19
11:35
Options
Cloudera put volume heavy and directionally bearish »

Bearish flow noted in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Dec

  • 09

    Dec

WMT

Walmart

$120.42

1.53 (1.29%)

11:31
11/18/19
11/18
11:31
11/18/19
11:31
Periodicals
Breaking Periodicals news story on Walmart »

At least three people…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TMUS

T-Mobile

$78.07

0.02 (0.03%)

11:27
11/18/19
11/18
11:27
11/18/19
11:27
Recommendations
T-Mobile analyst commentary  »

T-Mobile CEO transition…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Nov

  • 18

    Nov

  • 09

    Dec

LB

L Brands

$18.05

-0.03 (-0.17%)

11:25
11/18/19
11/18
11:25
11/18/19
11:25
Options
L Brands call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Nov

  • 05

    Dec

ATTO

Atento

$2.83

(0.00%)

11:25
11/18/19
11/18
11:25
11/18/19
11:25
Conference/Events
Atento to host investor day »

Investor day to be held…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Nov

MDCO

The Medicines Co.

$55.12

3.2 (6.16%)

11:25
11/18/19
11/18
11:25
11/18/19
11:25
Conference/Events
The Medicines Co. to host conference call »

Management discusses…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Nov

TMUS

T-Mobile

$78.12

0.07 (0.09%)

11:21
11/18/19
11/18
11:21
11/18/19
11:21
Recommendations
T-Mobile analyst commentary  »

Legere's departure…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Nov

  • 18

    Nov

  • 09

    Dec

$NSD

NASDAQ Market Internals

$0.00

(0.00%)

11:17
11/18/19
11/18
11:17
11/18/19
11:17
Technical Analysis
NASDAQ market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

$0.00

(0.00%)

11:16
11/18/19
11/18
11:16
11/18/19
11:16
Technical Analysis
NYSE market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

11:15
11/18/19
11/18
11:15
11/18/19
11:15
General news
Chair Powell met with President Trump and Treasury Secretary Mnuchin »

Chair Powell met with…

11:15
11/18/19
11/18
11:15
11/18/19
11:15
General news
Breaking General news story  »

6-Month Bill Auction to…

11:15
11/18/19
11/18
11:15
11/18/19
11:15
General news
Breaking General news story  »

3-Month Bill Auction to…

LK

Luckin Coffee

$28.78

1.72 (6.36%)

11:09
11/18/19
11/18
11:09
11/18/19
11:09
Options
Heavy option volume in Luckin Coffee as display caffeine jitters »

Heavy option volume in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Nov

  • 20

    Nov

  • 21

    Nov

PTON

Peloton

$28.40

1.12 (4.11%)

11:05
11/18/19
11/18
11:05
11/18/19
11:05
Options
Peloton Interactive call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Dec

BA

Boeing

$373.21

1.66 (0.45%)

11:03
11/18/19
11/18
11:03
11/18/19
11:03
Hot Stocks
Boeing 'strongly disagrees' with OIG report conclusions about CST-100 Starliner »

In response to the Nov.…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TRP

TC Energy

$51.43

0.05 (0.10%)

11:00
11/18/19
11/18
11:00
11/18/19
11:00
Conference/Events
TC Energy management to meet with JPMorgan »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Nov

  • 21

    Nov

  • 22

    Nov

SPY

SPDR S&P 500 ETF Trust

$311.27

-0.56 (-0.18%)

, SPX

S&P 500

$0.00

(0.00%)

10:53
11/18/19
11/18
10:53
11/18/19
10:53
General news
Trump says negative rates, easing discussed in 'very good' meeting with Powell »

President Donald Trump…

SPY

SPDR S&P 500 ETF Trust

$311.27

-0.56 (-0.18%)

SPX

S&P 500

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CGC

Canopy Growth

$14.66

-0.665 (-4.34%)

10:50
11/18/19
11/18
10:50
11/18/19
10:50
Options
Bad trip for Canopy put seller after 10day 30% slide »

Bad trip for Canopy put…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Nov

LTS

Ladenburg Thalmann

$3.48

(0.00%)

10:49
11/18/19
11/18
10:49
11/18/19
10:49
Downgrade
Ladenburg Thalmann rating change  »

Ladenburg Thalmann…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TWTR

Twitter

$29.33

0.08 (0.27%)

10:45
11/18/19
11/18
10:45
11/18/19
10:45
Options
Twitter call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Feb

10:45
11/18/19
11/18
10:45
11/18/19
10:45
General news
FX Action: USD-CAD »

FX Action: USD-CAD was…

AMRN

Amarin

$23.72

-0.275 (-1.15%)

10:44
11/18/19
11/18
10:44
11/18/19
10:44
Recommendations
Amarin analyst commentary  »

Roth says Amarin's…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Nov

  • 28

    Dec

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.